Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Hepatitis C

Case-finding intervention helps GPs identify and treat patients with hepatitis C

Researchers have concluded that scaling up hepatitis C treatment and case-finding in primary care is critical to achieving targets to eliminate the disease

Hepatitis C virus SPL20

Source: Cavallini James / BSIP / Science Photo Library

Researchers have tested an intervention to find and refer cases of hepatitis C in the community

An intervention designed to help GPs to identify and refer patients for hepatitis C (HCV) testing and treatment is both effective and cost-effective, research published in the BMJ (26 February 2020) has found[1].

Researchers compared the intervention with usual care across 45 general practices in south west England.

The intervention involved an electronic algorithm designed to flag patients with HCV risk markers. The tool also enabled practices to invite flagged patients for a test. Staff at practices in the intervention group received HCV training, and posters and patient leaflets were placed in waiting rooms.

Around 5% (24,473) of all patients were flagged as having HCV risk markers; 16% of the flagged patients in intervention practices were tested for HCV compared with 10% in control practices (adjusted rate ratio 1.59, 95% confidence interval 1.21–2.08).

The researchers calculated that there was one extra HCV diagnosis, referral and assessment per 792 patients flagged. On average, the intervention cost £3,165 per additional patient assessed at hepatology, with a cost per quality-adjusted life-year gained of £6,212.

Matt Hickman, public health epidemiologist at the University of Bristol and one of the authors of the study, said: “Scaling up HCV treatment and case-finding in primary care and other sites is critical to achieving ambitious targets to eliminate HCV as a public health problem.” 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20207847

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.